Table 3.

Baseline biochemical parameters of patients depending on Lp(a) quartiles.

Lp(а), quartiles	Groups	Q1	Q2–3	Q4	р; Q4 vs. Q1
	All (n = 216)	6 (n = 54)	6–48 (n = 108)	$>$48 (n = 54)
	Men (n = 96)	5 (n = 24)	5–41.5 (n = 48)	$>$41.5 (n = 24)
	Women (n = 120)	7 (n = 30)	7–51.5 (n = 60)	$>$51.5 (n = 30)
TC, mg/dL	All	189.9 $\pm$ 50.4	205.8 $\pm$ 50.7	206.1 $\pm$ 55.0	NS
	Men	202.2 $\pm$ 49.8	192.3 $\pm$ 52.3	203.7 $\pm$ 56.9	NS
	Women	188.8 $\pm$ 46.1	211.6 $\pm$ 52.0	207.4 $\pm$ 49.5	NS
TG, mg/dL	All	159 (109.0–225.0)	160.5 (120.5–226.0)	130.5 (101.0–236.0)	NS
	Men	185.5 (108.0–279.5)	160.5 (103.0–228.0)	124.5 (102.0–188.5)	NS
	Women	149.5 (118.0–222.0)	159.0 (113.0–217.0)	138.5 (107.0–237.0)	NS
HDL-C, mg/dL	All	44.7 $\pm$ 11.7	47.9 $\pm$ 12.8	47.9 $\pm$ 13.8	NS
	Men	40.1 $\pm$ 9.3	42.1 $\pm$ 8.9	42.9 $\pm$ 8.7	NS
	Women	48.8 $\pm$ 11.7**	53.5 $\pm$ 14.0***	52.6 $\pm$ 15.8**	NS
VLDL-C, mg/dL	All	32.0 (22.0–45.0)	32.0 (24.0–45.5)	26.0 (20.0–47.0)	NS
	Men	37.5 (21.5–56.0)	32.0 (20.5–47.5)	25.0 (20.5–37.5)	NS
	Women	29.5 (24.0–44.0)	32.0 (23.0–43.0)	27.5 (21.0–47.0)	NS
LDL-C, mg/dL	All	114.7 $\pm$ 41.6	119.6 $\pm$ 47.9	119.2 $\pm$ 50.5	NS
	Men	110.7 $\pm$ 40.1	112.4 $\pm$ 49.8	126.1 $\pm$ 52.5	NS
	Women	115.4 $\pm$ 38.8	125.7 $\pm$ 48.9	123.4 $\pm$ 46.1	NS
ApoA-I, mg/dL	All	147.2 $\pm$ 28.8	152.3 $\pm$ 28.5	164.0 $\pm$ 34.2	NS
	Men	137.1 $\pm$ 22.8	136.4 $\pm$ 15.8	144.2 $\pm$ 20.4	NS
	Women	165.1 $\pm$ 26.9***	167.1 $\pm$ 35.9***	171.2 $\pm$ 28.9***	NS
ApoB, mg/dL	All	112.0 $\pm$ 32.3	108.6 $\pm$ 28.4	109.0 $\pm$ 31.7	NS
	Men	108.4 $\pm$ 28.4	111.7 $\pm$ 37.3	110.9 $\pm$ 28.1	NS
	Women	116.1 $\pm$ 20.3	106.2 $\pm$ 27.8	111.8 $\pm$ 29.4	NS
ApoB/Apo-AI	All	0.78 $\pm$ 0.23	0.74 $\pm$ 0.28	0.69 $\pm$ 0.27	NS
	Men	0.86 $\pm$ 0.21	0.82 $\pm$ 0.26	0.79 $\pm$ 0.20	NS
	Women	0.72 $\pm$ 0.18*	0.69 $\pm$ 0.29*	0.68 $\pm$ 0.19*	NS
2-Δ⁢Δ⁢Ct	All	5.45 $\pm$ 1.56	5.16 $\pm$ 1.42	4.08 $\pm$ 1.42	р 0.001
	Men	5.65 $\pm$ 1.64	5.19 $\pm$ 1.40	4.27 $\pm$ 1.39	р 0.01
	Women	5.33 $\pm$ 1.43	5.00 $\pm$ 1.43	4.13 $\pm$ 1.68	р 0.01
Glucose, mmol/L	All	5.4 (4.9–6.3)	5.5 (5.0–6.35)	5.4 (4.9–6.1)	NS
	Men	5.4 (4.9–6.2)	5.5 (5.1–6.8)	5.4 (5.0–5.8)	NS
	Women	5.4 (5.0–6.3)	5.4 (5.0–6.0)	5.4 (5.0–6.7)	NS
Insulin, mUl/mL	All	14.9 (11.4–21.3)	14.9 (10.4–23.4)	14.5 (11.0–17.2)	NS
	Men	16.7 (12.7–21.3)	17.3 (10.6–25.5)	15.7 (10.4–21.9)	NS
	Women	13.7 (11.4–20.0)	12.7 (10.3–19.5)	14.9 (11.5–18.5)	NS
hsCRP, mg/L	All	2.5 (0.9–5.0)	4.5 (2.1–6.8)	3.3 (2.0–6.6)	NS
	Men	3.0 (1.4–5.3)	2.8 (1.4–6.4)	3.6 (2.0–6.6)	NS
	Women	2.0 (1.2–6.3)	4.7 (2.5–6.7)	3.5 (2.5–7.5)	NS
PCSK9, ng/mL	All	224.5 (156.0–343.0)	193.5 (138.5–280.5)	225.0 (148.0–361.0)	NS
	Men	178.0 (140.0–245.0)	169.0 (133.0–254.0)	219.0 (129.0–270.0)	NS
	Women	258.0 (147.0–387.0)	238.0 (177.0–330.0)	227.0 (148.0–446.0)	NS
Vitamin D, ng/mL	All	21.1 (14.4–26.4)	21.3 (15.4–30.2)	18.5 (13.2–26.8)	NS
	Men	22.7 (16.6–26.8)	21.08 (16.1–25.5)	19.1 (14.6–26.4)	NS
	Women	21.0 (11.3–25.8)	23.9 (15.2–33.2)	16.4 (11–26.8)	NS
Testosterone, ng/mL	All	2.5 (0.3–3.9)	0.3 (0.1–3.7)	0.4 (0.1–4.6)	NS
	Men	3.6 (2.6–4.4)	4.0 (3.0–4.6)	4.4 (3.0–5.0)	NS
	Women	0.3 (0.2–0.4)***	0.2 (0.04–0.2)***	0.1 (0.1–2.0)***	NS
Estradiol, pg/mL	All	15.5 (6.7–38.7)	7.0 (5.0–23.0)	19.9 (5.0–38.4)	NS
	Men	29.2 (15.5–38.7)	23.0 (17.2–35.2)	31.6 (26.7–42.8)	NS
	Women	5.0 (5.0–6.8)***	5.0 (5.0–7.0)***	5.0 (5.0–15.8)***	NS

*, p 0.05; **, p 0.01; ***, p 0.001 (intraquartile differences between males/females). NS, statistically non-significant between 4th and 1st quartiles. TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; Apo, apolipoprotein; hsCRP, high-sensitive C-reactive protein; Lp(a), lipoprotein(a); PCSK9, proprotein convertase subtilisin/kexin type 9.